Dergiler / Turkish Journal of Gastroenterology / 2019 / Cilt: 30 - Sayı: 8

Can the treatment duration be shortened in bismuthcontaining therapies for Helicobacter pylori eradication?

Sayfa
667–672
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Moreover, quinolone-containing therapies with the lowest eradication rate among the groups should not be offered asa salvage treatment in case of the BQT failure.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Background/Aims: The duration of Helicobacter pylori (H. pylori) eradication therapy as a range (e.g., 10–14 days) is an ignored problem.There is no any particular treatment duration described in current guidelines, and the conditions for when to use 10-day therapy vs.14-day therapy have not been elucidated.
📊
Temel Bulgular & Veri:There were four different treatment modalities administered to groups, and success rates were compared.Materials and Methods: Patients were eligible to participate in the study if they had a biopsy-proven H. pylori infection.
💡
Sonuç & Katkı:Moreover, quinolone-containing therapies with the lowest eradication rate among the groups should not be offered asa salvage treatment in case of the BQT failure.
🔬Tür:Uygulamalı Anket & Alan Araştırması
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Background/Aims: The duration of Helicobacter pylori (H. pylori) eradication therapy as a range (e.g., 10–14 days) is an ignored problem.There is no any particular treatment duration described in current guidelines, and the conditions for when to use 10-day therapy vs.14-day therapy have not been elucidated. The aim of this study is to determine an effective and reliable H. pylori treatment duration inclinical practice. There were four different treatment modalities administered to groups, and success rates were compared.Materials and Methods: Patients were eligible to participate in the study if they had a biopsy-proven H. pylori infection. Each patientwas randomly assigned to one of the four treatment groups according to a predetermined sequence: 14-day or 10-day bismuth-containing quadruple therapy (BQT) groups and 14-day or 10-day moxifloxacin-bismuth-combined treatment (MBCT) groups.Results: A total of 216 patients (54 per group) were enrolled. Two-hundred six patients (95.3%) completed therapy. There was no significant difference in the eradication rates between those patients who received 10- and 14-days BQT regimens (p=0.67). The 14-BQTprotocol had the highest eradication rate, the MBCT regimes had the highest compliance, and the 10-MBCT protocol had the poorestresults for H. pylori eradication. The posttreatment questionnaire on adverse effects identified nausea/vomiting as the most commonside effect (35.7%).Conclusion: Overall, the results of our study suggest that shortening the BQT protocol duration to 10 days does not weaken the H. pylorieradication rate. Moreover, quinolone-containing therapies with the lowest eradication rate among the groups should not be offered asa salvage treatment in case of the BQT failure.

🔖

Bu Makaleye Atıf Yap

ETİK, D. Ö., SEZEN, S., SUNA, N., ÖZTAŞ, E., KILIÇ, Z. M. Y. (2019). Can the treatment duration be shortened in bismuthcontaining therapies for Helicobacter pylori eradication?. Turkish Journal of Gastroenterology, Cilt: 30 - Sayı: 8, 667–672. https://ajindex.com/articles/408828

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (13)

  1. World Gastroenterology Organisation Global Guideline Helicobacter pylori in Developing Countries. Journal of Digestive Diseases 2011
  2. [CrossRef] 2. Ozaydin N, Turkyilmaz SA, Cali S. Prevalence and risk factors of Helicobacter pylori in Turkey: a nationally-representative, cross-sectional, screening with the 13C. BMC Public Health 2013
  3. [CrossRef] 3. Bor S, Vardar R, Ormeci N, et al. Prevalence patterns of gastric cancers in Turkey: model of a developing country with high occurrence of Helicobacter pylori. J Gastroenterol Hepatol 2007
  4. [CrossRef] 4. Available from: globocan.iarc.fr/old/FactSheets/cancers/stomach-new.asp 5. Malfertheiner P, Megraud F, O’Morain CA, et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut 2017
  5. [CrossRef] 6. Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol 2017
  6. [CrossRef] 7. Fock KM, Katelaris P, Sugano K, et al. Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol 2009
  7. [CrossRef] 8. Fu W, Song Z, Zhou L, et al. Randomized Clinical Trial: Esomeprazole, Bismuth, Levofloxacin, and Amoxicillin or Cefuroxime as FirstLine Eradication Regimens for Helicobacter pylori Infection. Dig Dis Sci 2017
  8. [CrossRef] 9. Su J, Zhou X, Chen H, Hao B, Zhang W, Zhang G. Efficacy of 1stline bismuth-containing quadruple therapies with levofloxacin or clarithromycin for the eradication of Helicobacter pylori infection: A 1-week, open-label, randomized trial. Medicine (Baltimore) 2017
  9. e5859. [CrossRef] 10. Liou JM, WU MS, Lin JT. Treatment of helicobacter pylori infection: Where are we now? J Gastroent Hepatol 2016
  10. [CrossRef] 11. Smith SM, O’Morian C, McNamara D. Antimicrobial susceptibility testing for Helicobacter pylori in times of increasing antibiotic resistance. World J Gastroenterol 2014
  11. [CrossRef] 12. El-Zimaity HM, Graham DY. Evaluation of gastric mucosal biopsy site and number for identification of Helicobacter pylori or intestinal metaplasia: role of the Sydney System. Hum Pathol 1999
  12. [CrossRef] 13. Kocazeybek B, Tokman HB. Prevelance of primaryantimicrobial resistance of H. pylori in Turkey: A systematic review. Helicobacter 2016
  13. [CrossRef] 14. Hu Y, Wan JH, Li XY, et al. Systematic review with meta-analysis: the global recurrenc